Ono Neuromed

Ono Neuromed is an Israeli neurotechnology company pioneering non-invasive, closed-loop brain stimulation therapy that adapts in real-time to individual neural activity patterns. The company's proprietary platform integrates EEG brain monitoring with transcranial stimulation technology to create personalized treatment protocols that respond dynamically to detected biomarkers. By combining real-time neural feedback with adaptive stimulation, Ono Neuromed delivers targeted therapy without the invasiveness of surgical implants, positioning itself at the forefront of precision neuromedicine.

Founded and based in Tel Aviv, Ono Neuromed secured $18 million in Series A funding to advance its clinical-stage brain-computer interface platform for psychiatric and neurological disorders. The company is focused on expanding its clinical validation pipeline and manufacturing capabilities to bring its adaptive stimulation technology to patients suffering from conditions where conventional treatments have proven insufficient. This funding milestone reflects growing investor confidence in closed-loop neuromodulation as a transformative approach to treating complex brain disorders.

Ono Neuromed addresses a critical gap in neurotechnology by demonstrating that effective brain treatment doesn't require invasive electrodes or permanent implants. The company's non-invasive, personalized approach challenges the limitations of current one-size-fits-all psychiatry and neurology treatments, offering hope for patients with treatment-resistant conditions. As the neurotech industry increasingly recognizes the potential of real-time neural feedback systems, Ono Neuromed's closed-loop technology represents a significant step toward truly individualized brain medicine at scale.